Loading...
The FDA has approved the first of a new class of drugs called integrase inhibitors for use in combination with other antiretroviral drugs to treat HIV infection, according to Merck, its manufacturer.
The drug, raltegravir (Isentress), should be available within 2 weeks, reports the Associated Press. It is intended for use in treatment-experienced adults who have evidence of HIV replication and resistance to multiple antiretroviral therapies.
The integrase inhibitor blocks an enzyme necessary for insertion of HIV DNA into human DNA. Approval was based on a 24-week analysis of clinical trial data showing that raltegravir significantly reduced viral load and increased CD4-cell counts.
The drug has not been shown to affect disease progression, and safety and efficacy have not been demonstrated in treatment-naïve patients or children.
Comment
LINK(S):
Merck press release (Free)
Associated Press story (Free)